Taysha Gene Therapies, Inc. (TSHA) Q4 2024 Earnings Conference Call
On February 26, 2025, at 8:30 AM ET, Taysha Gene Therapies, Inc. (TSHA) held its Full Year 2024 Conference Call. The participants from Taysha included Hayleigh Collins as the Director & Head of Investor Relations, Sean Nolan as the Chief Executive Officer, Sukumar Nagendran as the President & Head of R&D, and Kamran Alam as the Chief Financial Officer. The conference call was moderated by an operator, and the following analysts participated: Kristen Kluska from Cantor Fitzgerald, Salveen Richter from Goldman Sachs, Chris Raymond from Piper Sandler, Gil Blum from Needham & Company, Maury Raycroft from Jefferies, Yanan Zhu from Wells Fargo Securities, and Jack Allen from Baird. Silvan Tuerkcan from JMP also attended the call.
Company Overview
Taysha Gene Therapies is a clinical-stage gene therapy company focused on developing and commercializing gene therapies for monogenic CNS disorders, a group of rare and devastating neurological disorders. The company’s pipeline consists of three programs: TSHF011 for the treatment of X-linked adrenoleukodystrophy (X-ALD), TSHF115 for the treatment of ADA-SCID, and TSHF121 for the treatment of MPS IIIA.
Financial Results
During the conference call, Kamran Alam, the CFO, provided an overview of Taysha’s financial results for the fourth quarter and the full year 2024. For the fourth quarter, Taysha reported a net loss of $61.7 million, or $0.58 per share, compared to a net loss of $33.6 million, or $0.32 per share, in the same period in 2023. The increase in net loss was primarily due to higher research and development expenses related to the advancement of the company’s pipeline.
For the full year 2024, Taysha reported a net loss of $205.9 million, or $1.95 per share, compared to a net loss of $107.6 million, or $1.03 per share, in the same period in 2023. The increase in net loss was primarily due to higher research and development expenses, general and administrative expenses, and stock-based compensation.
Clinical Updates
The company also provided updates on the clinical progress of its pipeline. Sukumar Nagendran, the President & Head of R&D, announced that the company had completed dosing in the Phase 1/2 clinical trial of TSHF121 for the treatment of MPS IIIA. The data from this trial is expected to be presented at an upcoming medical conference in the second quarter of 2025. The company also plans to initiate a Phase 1/2 clinical trial for TSHF115 for the treatment of ADA-SCID in the second half of 2025.
Collaborations and Partnerships
Sean Nolan, the CEO, discussed the company’s collaborations and partnerships. He announced that Taysha had entered into a strategic collaboration with Novartis to develop and commercialize gene therapies for inherited retinal diseases. Under the terms of the agreement, Novartis will make an upfront payment of $150 million to Taysha, and Taysha will be eligible to receive potential milestone payments and royalties on net sales.
Impact on Individuals
For individuals with monogenic CNS disorders, the progress made by Taysha Gene Therapies in the development of gene therapies for X-ALD, ADA-SCID, and MPS IIIA is a significant step forward. These disorders can cause debilitating symptoms and, in some cases, early death. The availability of effective gene therapies could offer hope for those affected and their families.
Impact on the World
The progress made by Taysha Gene Therapies in the development of gene therapies for monogenic CNS disorders could have a significant impact on the world. Monogenic CNS disorders are a group of rare and devastating neurological disorders, and there are currently no effective treatments for many of them. The development of gene therapies could offer a new approach to treating these disorders and could lead to better outcomes for patients.
- Taysha Gene Therapies reported financial results for the fourth quarter and full year 2024, with a net loss of $205.9 million for the full year.
- The company provided updates on the clinical progress of its pipeline, including the completion of dosing in the Phase 1/2 clinical trial of TSHF121 for the treatment of MPS IIIA.
- Taysha entered into a strategic collaboration with Novartis to develop and commercialize gene therapies for inherited retinal diseases.
- The progress made by Taysha in the development of gene therapies for monogenic CNS disorders could offer hope for individuals with these disorders and their families.
- The development of gene therapies for monogenic CNS disorders could have a significant impact on the world by offering a new approach to treating these disorders and leading to better outcomes for patients.
Conclusion
In conclusion, Taysha Gene Therapies’ Full Year 2024 Conference Call provided important updates on the company’s financial results, clinical progress, and collaborations. The completion of dosing in the Phase 1/2 clinical trial of TSHF121 for the treatment of MPS IIIA and the strategic collaboration with Novartis are significant milestones for the company. The progress made by Taysha in the development of gene therapies for monogenic CNS disorders offers hope for individuals with these disorders and their families and could have a significant impact on the world by offering a new approach to treating these disorders and leading to better outcomes for patients.
As a reminder, Taysha Gene Therapies is a clinical-stage gene therapy company focused on developing and commercializing gene therapies for monogenic CNS disorders. Its pipeline consists of three programs: TSHF011 for the treatment of X-ALD, TSHF115 for the treatment of ADA-SCID, and TSHF121 for the treatment of MPS IIIA.
